Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

BACKGROUND Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population. METHODS These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8-10, and prostate-specific antigen [PSA]…

• P
  Pfizer
• AP
  Astellas Pharma US
• S
  Sanofi
• RM
  Royal Marsden NHS Foundation Trust
• CO
  Clovis Oncology
• CR
  Cancer Research UK
• NI
  National Institute for Health and Care Research
• AP
  Astellas Pharma
• SA
  Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
• MR
  Medical Research Council

  Award: MC_UU_00004/01
• JP
  Janssen Pharmaceuticals